Kristen L. Alexander - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
VP, Finance and Accounting
Signature
/s/ Kristen L. Alexander
Issuer symbol
LXRX
Transactions as of
28 Feb 2023
Net transactions value
-$11,566
Form type
4
Filing time
01 Mar 2023, 15:56:29 UTC
Previous filing
13 Feb 2023
Next filing
12 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +5,400 +32% 22,363 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +2,700 +12% 25,063 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +10,617 +42% 35,680 28 Feb 2023 Direct F1
transaction LXRX Common Stock Tax liability $11,566 -5,330 -15% $2.17 30,350 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -5,400 -100% 0 28 Feb 2023 Common Stock 5,400 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -2,700 -50% 2,700 28 Feb 2023 Common Stock 2,700 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -10,617 -33% 21,233 28 Feb 2023 Common Stock 10,617 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.